Trials / Recruiting
RecruitingNCT05618041
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd. · Industry
- Sex
- All
- Age
- 14 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.
Detailed description
Main research purposes: To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies. Secondary research purposes: Objective Evaluation of Cytodynamic Characteristics of CAR-T in Different Types of Hematological Malignancies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAR-T Autologous T cell injection | Biological: CAR-T; Drug: Cyclophosphamide,Fludarabine；Procedure: Leukapheresis |
Timeline
- Start date
- 2022-09-07
- Primary completion
- 2027-09-06
- Completion
- 2027-12-06
- First posted
- 2022-11-16
- Last updated
- 2025-06-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05618041. Inclusion in this directory is not an endorsement.